

Andrew J Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7504958/publications.pdf>

Version: 2024-02-01

45
papers

7,413
citations

201575

27
h-index

289141

40
g-index

50
all docs

50
docs citations

50
times ranked

10520
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. <i>Journal of Medical Genetics</i> , 2022, 59, 632-643.	1.5	33
2	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
3	Predicting the Likelihood of Carrying a <i>BRCA1</i> or <i>BRCA2</i> Mutation in Asian Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1542-1551.	0.8	14
4	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. <i>Breast Cancer Research</i> , 2021, 23, 22.	2.2	49
5	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab021.	1.4	19
6	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. <i>Genetics in Medicine</i> , 2021, 23, 2114-2121.	1.1	9
7	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. <i>Journal of Personalized Medicine</i> , 2021, 11, 916.	1.1	8
8	Performance of Breast Cancer Polygenic Risk Scores in 760 Female <i>CHEK2</i> Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 893-899.	3.0	21
9	CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 469-473.	1.1	98
10	Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models. <i>Cancers</i> , 2021, 13, 5194.	1.7	7
11	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	0.8	270
12	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. <i>Cancers</i> , 2020, 12, 1241.	1.7	19
13	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. <i>PLoS ONE</i> , 2020, 15, e0229999.	1.1	40
14	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. <i>Genetics in Medicine</i> , 2020, 22, 1803-1811.	1.1	49
15	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	3.0	106
16	Title is missing!. , 2020, 15, e0229999.		0
17	Title is missing!. , 2020, 15, e0229999.		0
18	Title is missing!. , 2020, 15, e0229999.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229999.		0
20	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
21	Homeobox B13 G84E Mutation and Prostate Cancer Risk. European Urology, 2019, 75, 834-845.	0.9	28
22	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 2019, 21, 1708-1718.	1.1	415
23	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	3.0	138
24	pedigreejs: a web-based graphical pedigree editor. Bioinformatics, 2018, 34, 1069-1071.	1.8	9
25	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	1.5	38
26	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
27	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
28	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
29	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 404-412.	1.1	341
30	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
31	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
32	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
33	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genetics in Medicine, 2016, 18, 1190-1198.	1.1	80
34	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Research and Treatment, 2016, 158, 463-469.	1.1	24
35	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
36	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125

#	ARTICLE	IF	CITATIONS
37	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
38	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
39	A risk prediction algorithm for ovarian cancer incorporating <i>BRCA1</i> , <i>BRCA2</i> , common alleles and other familial effects. <i>Journal of Medical Genetics</i> , 2015, 52, 465-475.	1.5	52
40	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
41	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
42	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	13.9	745
43	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.. <i>Journal of Clinical Oncology</i> , 2014, 32, 22-22.	0.8	0
44	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
45	Profile study: Genetic prostate cancer risk stratification for targeted screening.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5054-5054.	0.8	0